Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 4, 2022

Provention Bio Announces the Grant of Inducement Award
Feb 1, 2022

Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting

Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria
Jan 28, 2022

Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer
Jan 27, 2022

Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

- Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET -
Jan 20, 2022

Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)

- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases -

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.